Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
A phase II study of bromocriptine in patients with androgen-independent prostate cancer.
Horti J, Figg WD, Weinberger B, Kohler D, Sartor O. Horti J, et al. Among authors: sartor o. Oncol Rep. 1998 Jul-Aug;5(4):893-6. doi: 10.3892/or.5.4.893. Oncol Rep. 1998. PMID: 9625840 Clinical Trial.
Suramin rapidly alters cellular tyrosine phosphorylation in prostate cancer cell lines.
Sartor O, McLellan CA, Myers CE, Borner MM. Sartor O, et al. J Clin Invest. 1992 Dec;90(6):2166-74. doi: 10.1172/JCI116102. J Clin Invest. 1992. PMID: 1281826 Free PMC article.
A pilot study of interferon alfa-2a in combination with fluorouracil plus high-dose leucovorin in metastatic gastrointestinal carcinoma.
Grem JL, McAtee N, Murphy RF, Balis FM, Steinberg SM, Hamilton JM, Sorensen JM, Sartor O, Kramer BS, Goldstein LJ, et al. Grem JL, et al. Among authors: sartor o. J Clin Oncol. 1991 Oct;9(10):1811-20. doi: 10.1200/JCO.1991.9.10.1811. J Clin Oncol. 1991. PMID: 1919632
Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer.
Sartor O, Cooper M, Weinberger M, Headlee D, Thibault A, Tompkins A, Steinberg S, Figg WD, Linehan WM, Myers CE. Sartor O, et al. J Natl Cancer Inst. 1994 Feb 2;86(3):222-7. doi: 10.1093/jnci/86.3.222. J Natl Cancer Inst. 1994. PMID: 7506794
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Figg WD, Thibault A, Cooper MR, Reid R, Headlee D, Dawson N, Kohler DR, Reed E, Sartor O. Figg WD, et al. Among authors: sartor o. Cancer. 1995 Apr 15;75(8):2159-64. doi: 10.1002/1097-0142(19950415)75:8<2159::aid-cncr2820750820>;2-o. Cancer. 1995. PMID: 7535186 Clinical Trial.
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
Figg WD, Sartor O, Cooper MR, Thibault A, Bergan RC, Dawson N, Reed E, Myers CE. Figg WD, et al. Among authors: sartor o. Am J Med. 1995 Apr;98(4):412-4. doi: 10.1016/S0002-9343(99)80323-4. Am J Med. 1995. PMID: 7535978 Clinical Trial. No abstract available.
Antigrowth factor strategies.
Myers C, Trepel J, Sartor O, Cooper M, Ranson M, Toko T, Linehan MW. Myers C, et al. Among authors: sartor o. Cancer. 1993 Feb 1;71(3 Suppl):1172-8. doi: 10.1002/1097-0142(19930201)71:3+<1172::aid-cncr2820711441>;2-z. Cancer. 1993. PMID: 7679041 Clinical Trial. No abstract available.
Drug-induced apoptosis is not necessarily dependent on macromolecular synthesis or proliferation in the p53-negative human prostate cancer cell line PC-3.
Borner MM, Myers CE, Sartor O, Sei Y, Toko T, Trepel JB, Schneider E. Borner MM, et al. Among authors: sartor o. Cancer Res. 1995 May 15;55(10):2122-8. Cancer Res. 1995. PMID: 7743512
In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells and its potentiation by phenylbutyrate.
Figg WD, Walls RG, Cooper MR, Thibault A, Sartor O, McCall NA, Myers CE, Samid D. Figg WD, et al. Among authors: sartor o. Anticancer Drugs. 1994 Jun;5(3):336-42. doi: 10.1097/00001813-199406000-00012. Anticancer Drugs. 1994. PMID: 7919459
The detergent Triton X-100 induces a death pattern in human carcinoma cell lines that resembles cytotoxic lymphocyte-induced apoptosis.
Borner MM, Schneider E, Pirnia F, Sartor O, Trepel JB, Myers CE. Borner MM, et al. Among authors: sartor o. FEBS Lett. 1994 Oct 17;353(2):129-32. doi: 10.1016/0014-5793(94)01023-4. FEBS Lett. 1994. PMID: 7926036